Presentation Title

A DNA Vaccine Approach To Toxoplasma gondii

Presenter Information

Rosalie WarnerFollow

Advisor Information

Paul Davis

Location

UNO Criss Library, Room 232

Presentation Type

Oral Presentation

Start Date

2-3-2018 11:00 AM

End Date

2-3-2018 11:15 AM

Abstract

A DNA VACCINE APPROACH TO TOXOPLASMA GONDII

Rosalie C. Warner and Paul H. Davis, Department of Biology, University of Nebraska at Omaha, NE 68182

Toxoplasma gondii is an obligate intracellular parasite that has the ability to infect all nucleated mammalian cells and is found worldwide. This protozoan parasite can cause severe ocular and neurological disease in immunocompromised persons and fetuses. While there are treatments available for individuals infected with the tachyzoite stage of the parasite, which defines the acute infection, there is no effective way to treat for the latent cyst forming stage which is associated with behavioral changes. Thus, there is a need for an effective protective vaccine. This work highlights the design of a versatile DNA sequence that will function in conjunction with a novel delivery system that seeks to stimulate T cell- and antibody-mediated memory responses at mucosal pathogen entry sites. As multi-epitope DNA vaccines have been shown to provide effective protection against other pathogens, the developed sequence consists of three full length T. gondii genes, GRA7, SAG1, and MIC1 separated by tri-alanine linkers. The sequence is designed in such a way that the latter two genes are easily removed, allowing for observations of effects due to plasmid size. Also included in the vaccine design are a universal CD4+ T cell epitope (PADRE), a decapeptide derived from T. gondii gene GRA6 that has shown to produce an immunodominant and protective response (HF10), and CpG oligodeoxynucleotides that serve as a toll-like receptor agonist adjuvant. This design provides the optimal sequence for testing a DNA vaccine with a novel delivery system against T. gondii.

This document is currently not available here.

COinS
 
Mar 2nd, 11:00 AM Mar 2nd, 11:15 AM

A DNA Vaccine Approach To Toxoplasma gondii

UNO Criss Library, Room 232

A DNA VACCINE APPROACH TO TOXOPLASMA GONDII

Rosalie C. Warner and Paul H. Davis, Department of Biology, University of Nebraska at Omaha, NE 68182

Toxoplasma gondii is an obligate intracellular parasite that has the ability to infect all nucleated mammalian cells and is found worldwide. This protozoan parasite can cause severe ocular and neurological disease in immunocompromised persons and fetuses. While there are treatments available for individuals infected with the tachyzoite stage of the parasite, which defines the acute infection, there is no effective way to treat for the latent cyst forming stage which is associated with behavioral changes. Thus, there is a need for an effective protective vaccine. This work highlights the design of a versatile DNA sequence that will function in conjunction with a novel delivery system that seeks to stimulate T cell- and antibody-mediated memory responses at mucosal pathogen entry sites. As multi-epitope DNA vaccines have been shown to provide effective protection against other pathogens, the developed sequence consists of three full length T. gondii genes, GRA7, SAG1, and MIC1 separated by tri-alanine linkers. The sequence is designed in such a way that the latter two genes are easily removed, allowing for observations of effects due to plasmid size. Also included in the vaccine design are a universal CD4+ T cell epitope (PADRE), a decapeptide derived from T. gondii gene GRA6 that has shown to produce an immunodominant and protective response (HF10), and CpG oligodeoxynucleotides that serve as a toll-like receptor agonist adjuvant. This design provides the optimal sequence for testing a DNA vaccine with a novel delivery system against T. gondii.